Payment overview · 2025
General Payments
$590.28
31 reported records · 11 companies
Healthcare provider profile · identity verified
Mohammad Afzal, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOMERSET, KY · NPI 1245329069
Verified facts
What the public records show
CMS Open Payments records show Mohammad Afzal, MD received $590.28 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Nurtec Odt, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 235 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 323 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synjardy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 424 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.81 | 29.3% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $133.89 | 22.7% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $77.53 | 13.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.82 | 6.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.15 | 6.5% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.97 | 6.1% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $30.66 | 5.2% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.16 | 2.9% | 1 | 2025 |
| Reapplix Inc. | Unresolved — no canonical attribution shown | $16.48 | 2.8% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.96 | 2.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.85 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $590.28 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $158.85 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $134.18 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $133.89 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $120.22 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $77.53 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $60.12 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.82 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $38.15 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.97 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $30.66 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| 3C Patch Kit - Box Normalized: 3c patch kit box |
Device | Reapplix Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 424 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 235 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 323 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 123 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
235 | 45 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
323 | 44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
21 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
123 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
424 | 58 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 995 | 183 |
| Omeprazole | Omeprazole | 805 | 156 |
| Gabapentin | Gabapentin | 677 | 91 |
| Metformin Hcl | Metformin Hcl | 629 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 628 | 106 |
| Lisinopril | Lisinopril | 586 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 571 | 120 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 500 | 131 |
| Potassium Chloride | Potassium Chloride | 471 | 103 |
| Losartan Potassium | Losartan Potassium | 463 | 111 |
| Furosemide | Furosemide | 453 | 100 |
| Eliquis | Apixaban | 424 | 58 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 415 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 385 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 343 | 85 |
| Sertraline Hcl | Sertraline Hcl | 340 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 325 | 60 |
| Jardiance | Empagliflozin | 323 | 44 |
| Montelukast Sodium | Montelukast Sodium | 316 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 306 | 66 |
| Carvedilol | Carvedilol | 270 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 257 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 256 | 73 |
| Buspirone Hcl | Buspirone Hcl | 252 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 243 | 77 |
| Mirtazapine | Mirtazapine | 238 | 54 |
| Farxiga | Dapagliflozin Propanediol | 235 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 227 | 46 |
| Famotidine | Famotidine | 217 | 54 |
| Citalopram Hbr | Citalopram Hydrobromide | 215 | 32 |
| Simvastatin | Simvastatin | 201 | 39 |
| Clopidogrel | Clopidogrel Bisulfate | 199 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 179 | 36 |
| Ozempic | Semaglutide | 174 | 29 |
| Donepezil Hcl | Donepezil Hcl | 171 | 28 |
| Trazodone Hcl | Trazodone Hcl | 155 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 151 | 31 |
| Memantine Hcl | Memantine Hcl | 142 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 141 | 30 |
| Spironolactone | Spironolactone | 140 | 32 |
| Ventolin Hfa | Albuterol Sulfate | 138 | 35 |
| Alendronate Sodium | Alendronate Sodium | 134 | 29 |
| Ezetimibe | Ezetimibe | 133 | 33 |
| Hydralazine Hcl | Hydralazine Hcl | 132 | 31 |
| Atenolol | Atenolol | 124 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 124 | 21 |
| Linzess | Linaclotide | 124 | 25 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 123 | 30 |
| Mounjaro | Tirzepatide | 118 | 18 |
| Topiramate | Topiramate | 117 | 15 |
| Azithromycin | Azithromycin | 113 | 87 |
| Levetiracetam | Levetiracetam | 112 | 15 |
| Prednisone | Prednisone | 112 | 69 |
| Aripiprazole | Aripiprazole | 106 | 12 |
| Ibuprofen | Ibuprofen | 104 | 33 |
| Xarelto | Rivaroxaban | 102 | 17 |
| Vascepa | Icosapent Ethyl | 99 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 22 |
| Alprazolam | Alprazolam | 96 | 17 |
| Meloxicam | Meloxicam | 95 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 91 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 86 | 62 |
| Januvia | Sitagliptin Phosphate | 85 | suppressed |
| Loperamide | Loperamide Hcl | 85 | 28 |
| Lorazepam | Lorazepam | 85 | 17 |
| Baclofen | Baclofen | 84 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 84 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 83 | 41 |
| Celecoxib | Celecoxib | 82 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 82 | 26 |
| Tramadol Hcl | Tramadol Hcl | 80 | 13 |
| Methocarbamol | Methocarbamol | 77 | 27 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 76 | 22 |
| Finasteride | Finasteride | 76 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 74 | 19 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 73 | 14 |
| Latanoprost | Latanoprost | 72 | suppressed |
| Pregabalin | Pregabalin | 71 | 12 |
| Allopurinol | Allopurinol | 70 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 70 | suppressed |
| Olanzapine | Olanzapine | 70 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 70 | 11 |
| Ondansetron Odt | Ondansetron | 68 | 31 |
| Metoclopramide Hcl | Metoclopramide Hcl | 67 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 66 | suppressed |
| Clonazepam | Clonazepam | 66 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 65 | 14 |
| Nifedipine Er | Nifedipine | 65 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 64 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 64 | 18 |
| Venlafaxine Hcl | Venlafaxine Hcl | 64 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 12 |
| Bupropion Xl | Bupropion Hcl | 62 | 15 |
| Bumetanide | Bumetanide | 61 | suppressed |
| Trulicity | Dulaglutide | 61 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 61 | 13 |
| Clonidine Hcl | Clonidine Hcl | 60 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 58 | 12 |
| Entresto | Sacubitril/Valsartan | 57 | suppressed |
| Nystatin | Nystatin | 57 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 56 | 16 |
| Metformin Hcl Er | Metformin Hcl | 54 | 13 |
| Nitroglycerin | Nitroglycerin | 54 | 29 |
| Risperidone | Risperidone | 54 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 22 |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 50 | 20 |
| Glimepiride | Glimepiride | 49 | 11 |
| Warfarin Sodium | Warfarin Sodium | 48 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 14 |
| Divalproex Sodium | Divalproex Sodium | 44 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 44 | 32 |
| Primidone | Primidone | 44 | suppressed |
| Digoxin | Digoxin | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 14 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 42 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Ranolazine Er | Ranolazine | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | 11 |
| Benazepril Hcl | Benazepril Hcl | 39 | suppressed |
| Cephalexin | Cephalexin | 39 | 29 |
| Lamotrigine | Lamotrigine | 39 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 11 |
| Chlorthalidone | Chlorthalidone | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 11 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 21 |
| Varenicline Tartrate | Varenicline Tartrate | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 27 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 32 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 18 |
| Cefuroxime | Cefuroxime Axetil | 30 | 26 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Tradjenta | Linagliptin | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 27 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 27 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 27 | suppressed |
| Verapamil Er | Verapamil Hcl | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Sotalol | Sotalol Hcl | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 23 | 13 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Galantamine Er | Galantamine Hbr | 22 | suppressed |
| Humalog | Insulin Lispro | 22 | suppressed |
| Novolin R | Insulin Regular, Human | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 21 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Humulin R | Insulin Regular, Human | 21 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 21 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Naproxen | Naproxen | 20 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 20 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Amantadine | Amantadine Hcl | 19 | suppressed |
| Klor-Con M10 | Potassium Chloride | 19 | suppressed |
| Lactulose | Lactulose | 19 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Zafirlukast | Zafirlukast | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 13 |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Clonidine | Clonidine | 15 | suppressed |
| Dexamethasone | Dexamethasone | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Admelog Solostar | Insulin Lispro | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Mresvia | Rsv Vaccine, Pref, Mrna/Pf | 13 | 13 |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Orencia Clickject | Abatacept | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Enulose | Lactulose | 11 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $590.28 · 31 records | AstraZeneca Pharmaceuticals LP | 3C Patch Kit - Box, AIRSUPRA, BREZTRI, ELIQUIS, FANAPT, FARXIGA, JARDIANCE, Kerendia, NUPLAZID, NURTEC ODT, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, YUPELRI, ZAVZPRET | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error